Idalopirdine for Alzheimer's disease: written in the stars. (Q53357594)

13 May 2018

title

Idalopirdine for Alzheimer's disease: written in the stars. (English)

1 reference

13 May 2018

0 references

Lon S Schneider

1

1 reference

13 May 2018

publication date

5 October 2014

1 reference

13 May 2018

published in

Lancet Neurology

1 reference

13 May 2018

volume

13

1 reference

13 May 2018

issue

11

1 reference

13 May 2018

page(s)

1063-1065

1 reference

13 May 2018

Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

Dimebon disappointment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970232-7

7 January 2021

10.1016/S1474-4422(14)70232-7

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018